Clinical Trials Browser

Phase 1/2 × Lymphoma × ixazomib × Clear all

NCT02898259 2022-09-26

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Phase 1/2 Terminated

19 enrolled 15 charts

Lymphoma, Lymphoma, B-Cell